Experimental gene 'Silencer' therapy enters human testing for rare muscle disease
NCT ID NCT06907875
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This early-phase trial is testing EPI-321, a one-time gene therapy designed to silence the faulty gene that causes facioscapulohumeral muscular dystrophy (FSHD). The study will enroll 12 adults with FSHD Type 1 to see if the treatment is safe and tolerable, and whether it shows any signs of working. Participants receive a single IV dose and are monitored for about 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EPI-321 (a gene therapy that aims to silence the faulty gene causing FSHD)
- What this could lead to
- If it works, this could point toward a treatment that stops or slows muscle damage in FSHD, a rare muscular dystrophy.
- What could go wrong
- This is a very early, small trial (12 people) focused on safety, not proof of effectiveness. The therapy is new and may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
David Geffen School of Medicine at University of California, Los Angeles
Los Angeles, California, 90095, United States
-
Kennedy Krieger Institute, Center for Genetic Muscle Disorders
Baltimore, Maryland, 21205, United States
-
Pacific Clinical Research Network
Auckland, New Zealand, 0622, New Zealand
-
Rare Disease Research
Atlanta, Georgia, 303329, United States
-
Royal Alfred Hospital
Sydney, New South Wales, 2050, Australia
-
University of Massachusetts Chan Medical School
Worcester, Massachusetts, 01605, United States
-
Utah Program for Inherited Neuromuscular Disorders - University of Utah
Salt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI reveal the hidden progression of muscular dystrophy?
- Personalized exercise program aims to boost mobility in rare muscle diseases
- New tools aim to speed up FSHD drug trials
- Inflammation may be key in rare muscle disease
- New tool could better track facial muscle health in rare muscle disease
- New drug aims to build muscle in rare muscular dystrophy